FAM174B remodels the tumor microenvironment, inhibits the infiltration of macrophage, predicts the molecular subtype and therapeutic response of bladder cancer
Open Access
- 11 August 2025
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (14) , 3737-3748
Abstract
Background: While the immunomodulatory function of FAM174B in bladder cancer (BLCA) has yet to be fully elucidated, elucidating its biological mechanisms could potentially enhance immunotherapeutic outcomes for this malignancy.Keywords
This publication has 23 references indexed in Scilit:
- Monitoring immune-checkpoint blockade: response evaluation and biomarker developmentNature Reviews Clinical Oncology, 2017
- Chemokines in the cancer microenvironment and their relevance in cancer immunotherapyNature Reviews Immunology, 2017
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2017
- Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder CancerCancer Immunology Research, 2016
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-AnalysisPLOS ONE, 2016
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung CancerJAMA Oncology, 2016
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- An immune-active tumor microenvironment favors clinical response to ipilimumabCancer Immunology, Immunotherapy, 2011